NZ601350A - Method of treating arthritis - Google Patents

Method of treating arthritis

Info

Publication number
NZ601350A
NZ601350A NZ601350A NZ60135008A NZ601350A NZ 601350 A NZ601350 A NZ 601350A NZ 601350 A NZ601350 A NZ 601350A NZ 60135008 A NZ60135008 A NZ 60135008A NZ 601350 A NZ601350 A NZ 601350A
Authority
NZ
New Zealand
Prior art keywords
treating arthritis
arthritis
medicament
abstract
variables
Prior art date
Application number
NZ601350A
Other languages
English (en)
Inventor
Philip Bardwell
Tariq Ghayur
Original Assignee
Abbvie Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Inc filed Critical Abbvie Inc
Publication of NZ601350A publication Critical patent/NZ601350A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
    • A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NZ601350A 2007-11-16 2008-11-14 Method of treating arthritis NZ601350A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US98847907P 2007-11-16 2007-11-16
NZ585085A NZ585085A (en) 2007-11-16 2008-11-14 Method of treating arthritis using arylsulfonamide compounds

Publications (1)

Publication Number Publication Date
NZ601350A true NZ601350A (en) 2013-08-30

Family

ID=40291332

Family Applications (2)

Application Number Title Priority Date Filing Date
NZ601350A NZ601350A (en) 2007-11-16 2008-11-14 Method of treating arthritis
NZ585085A NZ585085A (en) 2007-11-16 2008-11-14 Method of treating arthritis using arylsulfonamide compounds

Family Applications After (1)

Application Number Title Priority Date Filing Date
NZ585085A NZ585085A (en) 2007-11-16 2008-11-14 Method of treating arthritis using arylsulfonamide compounds

Country Status (14)

Country Link
US (2) US20090176785A1 (enExample)
EP (1) EP2231159A1 (enExample)
JP (2) JP5450434B2 (enExample)
KR (1) KR101585848B1 (enExample)
CN (1) CN101969951B (enExample)
AU (1) AU2008322595B2 (enExample)
CA (1) CA2705294C (enExample)
DO (1) DOP2013000169A (enExample)
IL (2) IL205501A (enExample)
MX (1) MX2010005395A (enExample)
NZ (2) NZ601350A (enExample)
RU (2) RU2472509C2 (enExample)
WO (1) WO2009064938A1 (enExample)
ZA (1) ZA201003434B (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
RU2015141713A (ru) * 2010-03-25 2018-12-28 Эббви Инк. Средства, индуцирующие апоптоз, для лечения рака, иммунных и аутоиммунных заболеваний
TWI520960B (zh) 2010-05-26 2016-02-11 艾伯維有限公司 用於治療癌症及免疫及自體免疫疾病之細胞凋亡誘導劑
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
CA3152557A1 (en) 2010-10-29 2012-05-03 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
PT2643322T (pt) 2010-11-23 2017-11-13 Abbvie Inc Sais e formas cristalinas de um agente indutor de apoptose
ES2603129T3 (es) 2010-11-23 2017-02-23 Abbvie Ireland Unlimited Company Métodos de tratamiento utilizando inhibidores selectivos de Bcl-2
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CN111511748B (zh) 2017-08-23 2023-05-02 广州麓鹏制药有限公司 Bcl-2抑制剂
US11903950B2 (en) 2018-08-22 2024-02-20 Newave Pharmaceutical Inc. BCL-2 inhibitors
WO2020140005A2 (en) 2018-12-29 2020-07-02 Newave Pharmaceutical Inc. Bcl-2 inhibitors
US20220372042A1 (en) 2019-10-03 2022-11-24 Newave Pharmaceutical Inc. Condensed heterocycles as bcl-2 inhibitors
KR20220098755A (ko) 2019-11-05 2022-07-12 애브비 인코포레이티드 나비토클락스를 사용한 골수섬유증 및 mpn 관련 장애 치료에 사용하기 위한 투약 레지멘
WO2021133817A1 (en) 2019-12-27 2021-07-01 Guangzhou Lupeng Pharmaceutical Company Ltd. 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases
JP7849296B2 (ja) 2020-02-24 2026-04-21 グアンジョウ・ルペン・ファーマシューティカル・カンパニー・リミテッド Ｂｃｌ２阻害剤を含むホットメルト押出し固体分散体
US20240166646A1 (en) 2020-12-22 2024-05-23 Newave Pharmaceutical Inc. 1h-pyrrolo[2,3-b]pyridine derivatives as bcl-2 inhibitors for the treatment of neoplastic and autoimmune diseases

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9200275D0 (en) * 1992-01-08 1992-02-26 Roussel Lab Ltd Chemical compounds
WO1997013751A1 (en) * 1995-10-10 1997-04-17 Pfizer Inc. Indole carbamates as leukotriene antagonists
NZ520657A (en) * 2000-03-21 2004-11-26 Procter & Gamble Heterocyclic side chain containing, N-substituted metalloprotease inhibitors
AU9598601A (en) * 2000-10-20 2002-04-29 Eisai Co Ltd Nitrogenous aromatic ring compounds
GB0217431D0 (en) * 2002-07-27 2002-09-04 Astrazeneca Ab Novel compounds
ATE403654T1 (de) * 2003-07-28 2008-08-15 Janssen Pharmaceutica Nv Benzimidazol-, benzothiazol- und benzoxazolderivate und deren verwendung als lta4h-modulatoren
KR100747401B1 (ko) * 2003-09-03 2007-08-08 화이자 인코포레이티드 프로스타글란딘 ｅ2 길항제로서의 페닐 또는 피리딜 아미드 화합물
WO2005049593A2 (en) * 2003-11-13 2005-06-02 Abbott Laboratories N-acylsulfonamide apoptosis promoters
ES2257929B1 (es) * 2004-07-16 2007-05-01 Laboratorios Del Dr. Esteve, S.A. Derivados de pirazolina, procedimiento para su obtencion y utilizacion de los mismos como agentes terapeuticos.
PL1888550T3 (pl) * 2005-05-12 2014-12-31 Abbvie Bahamas Ltd Promotory apoptozy
US20060276464A1 (en) * 2005-05-13 2006-12-07 Wyeth Diarylsulfone sulfonamides and use thereof
US20080182845A1 (en) * 2006-11-16 2008-07-31 Abbott Laboratories Method of preventing or treating organ, hematopoietic stem cell or bone marrow transplant rejection

Also Published As

Publication number Publication date
CA2705294A1 (en) 2009-05-22
WO2009064938A1 (en) 2009-05-22
RU2010123796A (ru) 2011-12-27
AU2008322595B2 (en) 2014-01-30
ZA201003434B (en) 2011-10-26
JP2014065716A (ja) 2014-04-17
JP5667684B2 (ja) 2015-02-12
IL205501A (en) 2013-08-29
JP5450434B2 (ja) 2014-03-26
AU2008322595A1 (en) 2009-05-22
CN101969951B (zh) 2012-10-31
IL205501A0 (en) 2010-12-30
MX2010005395A (es) 2010-06-02
NZ585085A (en) 2012-08-31
JP2011503199A (ja) 2011-01-27
RU2526201C2 (ru) 2014-08-20
US20090176785A1 (en) 2009-07-09
CN101969951A (zh) 2011-02-09
KR20100099172A (ko) 2010-09-10
RU2472509C2 (ru) 2013-01-20
DOP2013000169A (es) 2013-12-15
US20160101109A1 (en) 2016-04-14
KR101585848B1 (ko) 2016-01-15
IL227641A0 (en) 2013-09-30
RU2012143212A (ru) 2014-04-20
CA2705294C (en) 2016-05-17
WO2009064938A9 (en) 2009-08-06
EP2231159A1 (en) 2010-09-29

Similar Documents

Publication Publication Date Title
NZ601350A (en) Method of treating arthritis
MX2009007231A (es) Compuestos quimicos 637:piridopirimidindionas como inhibidores de la fosfodiesterasa 4.
NZ598972A (en) Spiro-indoline-piperidine derivatives as selective GPR-40 activators for treating diabetes
EA201201648A1 (ru) Стимуляторы sgc
MY156274A (en) COMPOUNDS FOR THE REDUCTION OF ß-AMYLOID PRODUCTION
MX2010002419A (es) (ciclopropilfenil) feniloxamidas, metodo para su produccion y uso como un medicamento.
MX2010002461A (es) (carboxilalquilenfenil)feniloxamidas, metodo para su produccion y uso de las mismas como medicamento.
MX343135B (es) Compuestos de tipo fumagilol y métodos de realización y uso de los mismos.
TN2009000132A1 (en) Substituted dihydropyrazolones for treating cardiovascular and haematological diseases
AU2011328009A8 (en) Compounds and methods for treating pain
MY158994A (en) Ampk modulators
EA201200102A1 (ru) Соединения, применимые в качестве лекарственных средств
TN2012000401A1 (en) Heterocyclic compound
TN2012000578A1 (en) Tetrahydro-pyrido-pyrimidine derivatives
TN2012000248A1 (en) Novel spiropiperidine compounds
HK1215579A1 (zh) 被取代的2，3-二氫苯並呋喃基化合物和其用途
PH12013500205A1 (en) Compounds and methods for skin repair
MY164641A (en) Use of sulphur-containing heteroaromatic acid analogues as bactericides
MX348024B (es) Compuestos de adamantilo.
WO2009074247A8 (de) Neue 2-aryl-thiazol-4-carbonsäureamid-derivate, deren herstellung und verwendung als arzneimittel
SG190947A1 (en) Compounds and methods for skin repair
MY146084A (en) Benzyl amines, a process for their production and their use as anti-inflammatory agents
WO2010072770A3 (en) Griseofulvin analogues for the treatment of cancer by inhibition of centrosomal clustering
MX2011012538A (es) Terapia de combinacion para el tratamiento del mieloma multiple.
WO2011000945A3 (en) Aminoalkamides for use in the treatment of inflammatory, degenerative or demyelinating diseases of the cns

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: ABBVIE INC., US

Effective date: 20130801

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 3 YEARS UNTIL 14 NOV 2015 BY SPRUSON + FERGUSON

Effective date: 20140110

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 14 NOV 2016 BY THOMSON REUTERS

Effective date: 20151030

LAPS Patent lapsed